BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with ...

BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...

The OraSure Board and management team are committed to moving the Company forward with a clear focus on shareholder value creation. We maintain open and constructive dialogue with our shareholders, ...

Flora Growth Corp. (NASDAQ: FLGC) surged 5.98% to $10.55 in after-hours trading on Thursday. Check out the current price of FLGC stock here. According to Benzinga Pro data, the stock of the ...

Creating One of the Largest Omni-Channel Retailers Across the Full Inclusive Sizing Market, with Approximately $1.2 Billion of Combined Annual ...

Treasury Secretary Scott Bessent said he expects the U.S. to end the year with a better-than-expected 3% gross domestic product (GDP) growth. Bessent appeared Sunday on CBS News' "Face the Nation" and ...

These three small-cap companies are at the forefront of autonomous drones, sidewalk robotics, and quantum computing. All three are posting triple-digit revenue growth while burning cash and trading at ...

The Vanguard Growth ETF has been a significant market beater. The Invesco QQQ Trust is heavily tech focused and can sometimes be volatile, but returns have been impressive. The Schwab U.S. Large-Cap ...

Investing in leading growth stocks can lead to large gains. For more than a decade now, growth stocks have been the driving force behind the market's run higher. As long as the bull market lasts, that ...

Destiny 3 and a form of “Classic” Destiny 2 experience are reportedly in the early stages of development at Bungie, according to leakers. The claim, originally made by a user known as Starsiza, stated ...